<DOC>
	<DOC>NCT01982968</DOC>
	<brief_summary>This study will test the hypothesis that treatment with laparoscopic anti-reflux surgery in subjects with idiopathic pulmonary fibrosis (IPF) and abnormal gastroesophageal reflux (GER) will slow the decline of forced vital capacity (FVC) over 48 weeks.</brief_summary>
	<brief_title>Treatment of IPF With Laparoscopic Anti-Reflux Surgery</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Confirmed diagnosis of idiopathic pulmonary fibrosis Abnormal GER on 24hour pH monitoring (DeMeester score &gt; 14.7) Able to provide informed consent Willing to undergo laparoscopic antireflux surgery FVC &lt; 50% predicted FEV1/FVC ratio &lt; 0.65 Resting room air PaO2 &lt; 60mm Hg Unable to walk 50 meters on 6 minute walk test Acute respiratory illness in last 12 weeks Experimental medication for IPF in last 28 days Listed for lung transplantation at screening Unable to safely undergo surgery History of esophageal / bariatric / gastric surgery History of cancer (other than nonmelanoma skin cancer) in last 3 years Pregnant at time of screening or enrollment Unable to obtain preauthorized approval from a third party payer for surgery and related costs Life expectancy &lt; 48 weeks due to another illness BMI &gt; 35 Known severe pulmonary hypertension (mean pressure &gt; 35 mm Jg on RHC; RVSP &gt; 50 mm Hg on ECHO)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Idiopathic pulmonary fibrosis</keyword>
	<keyword>IPF</keyword>
	<keyword>Gastroesophageal reflux</keyword>
	<keyword>GER</keyword>
	<keyword>GERD</keyword>
</DOC>